A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Compare the Efficacy and Safety of Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension

Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Compare the Efficacy and Safety of Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2017

At a glance

  • Drugs Treprostinil (Primary) ; Ambrisentan; Tadalafil
  • Indications Pulmonary arterial hypertension
  • Focus Therapeutic Use
  • Sponsors United Therapeutics Corporation
  • Most Recent Events

    • 31 Oct 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 10 Jun 2017 Biomarkers information updated
    • 19 May 2017 Planned initiation date changed from 1 Apr 2017 to 1 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top